DK0062498333
© Globe Newswire
12.12.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
News Preview
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2025
NOVO B
LISTED
CPH
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes
News Preview
Bagsværd, Denmark, 25 November 2025 – Novo Nordisk today announced positive headline results from a phase 2 clinical trial with amycretin in people with type 2 diabetes. This marks the first evaluation of amycretin in people with type 2 diabetes, further demonstrating Novo Nordisk’s commitment to advancing innovation in the treatment of type 2 diab...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.11.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression
News Preview
Bagsværd, Denmark, 24 November 2025 – Novo Nordisk today announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease. The two trials were randomised, double-blinded, enrolled a total of 3808 adults and evaluated the efficacy and safety of oral semaglutide compared...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
17.11.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
News Preview
Bagsværd, Denmark, 17 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons ha...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
14.11.2025
NOVO B
LISTED
CPH
Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S
News Preview
Bagsværd, Denmark, 14 November 2025 - Today, Novo Nordisk A/S held its Extraordinary General Meeting, which was convened to elect new members of the Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
13.11.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
News Preview
Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November...
Themefolio
Profiler
Peergroup
© Globe Newswire
11.11.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
News Preview
Bagsværd, Denmark, 11 November 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons ha...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.11.2025
NOVO B
LISTED
CPH
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
News Preview
Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.11.2025
NOVO B
LISTED
CPH
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
News Preview
Novo Nordisk has agreed with the U.S. Administration to lower drug prices beginning in 2026 and expand patient access and affordability for semaglutide ......
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
NOVO B
LISTED
CPH
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
News Preview
Novo Nordisk presented new findings from the STEP UP phase 3b trial. It showed that, in addition to losing an average of 21% of their body weight......
Themefolio
Profiler
Peergroup
© Globe Newswire
05.11.2025
NOVO B
LISTED
CPH
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues
News Preview
Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
NOVO B
LISTED
CPH
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
News Preview
Today, Novo Nordisk confirms that it has submitted an updated, unsolicited proposal to acquire Metsera. The updated proposal has been declared superior...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
30.10.2025
NOVO B
LISTED
CPH
Novo Nordisk submits proposal to acquire Metsera, Inc.
News Preview
Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera)....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.10.2025
NOVO B
LISTED
CPH
Notice convening an Extraordinary General Meeting of Novo Nordisk A/S
News Preview
Bagsværd, Denmark, 21 October 2025 – Further to company announcement no. 28 issued today, an Extraordinary General Meeting of Novo Nordisk A/S is called to elect new members to the Board of Directors in accordance with the meeting agenda and proposals included in the enclosed meeting notice....
Themefolio
Profiler
Peergroup
© Globe Newswire
15.10.2025
NOVO B
LISTED
CPH
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
News Preview
Bagsværd, Denmark and Seattle, US, 15 October 2025 – Novo Nordisk and Omeros Corporation (Nasdaq: OMER) today announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (formerly OMS906) in clinical development for rare blood and kidney disorders....
Themefolio
Profiler
Peergroup
© Globe Newswire
09.10.2025
NOVO B
LISTED
CPH
Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio
News Preview
Bagsværd, Denmark, 9 October, 2025 – Novo Nordisk today announced that it has entered into a definitive agreement to acquire Akero Therapeutics, Inc. (Akero), a publicly held clinical-stage company developing innovative treatments for patients with serious metabolic diseases marked by a high unmet medical need. Akero’s fibroblast growth factor 21 (...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.09.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study
News Preview
Bagsværd, Denmark, 18 September 2025 – Novo Nordisk today announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semaglutide) was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23%1. The data span nearly 60,000 US...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.09.2025
NOVO B
LISTED
CPH
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
News Preview
Bagsværd, Denmark, Plainsboro, NJ, 17 September 2025 – Today, The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the investigational once-daily oral semaglutide 25 mg (Wegovy® in a pill*), marking a significant milestone in the company’s ambition to advance obesity care....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.09.2025
NOVO B
LISTED
CPH
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme
News Preview
Bagsværd, Denmark, 16 September 2025 – Novo Nordisk today presented data from a sub-analysis of the phase 3 REDEFINE 1 trial at the European Association for the Study of Diabetes (EASD) congress 2025 from 15–19 September in Vienna, Austria. This sub-analysis evaluated the efficacy and safety of once-weekly cagrilintide 2.4 mg monotherapy, plus life...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
NOVO B
LISTED
CPH
People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being
News Preview
Bagsværd, Denmark, 16 September 2025 – Novo Nordisk today announced results from the US-based INFORM survey of people taking semaglutide for weight management (Wegovy®), at the European Association for the Study of Diabetes (EASD) 2025, Vienna, Austria. The INFORM survey revealed that individuals experienced a substantial drop in food noise after s...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.09.2025
NOVO B
LISTED
CPH
EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
News Preview
Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial. SOUL was a phase 3b trial carried out to evaluate the eff...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.09.2025
NOVO B
LISTED
CPH
Novo Nordisk to streamline operations and reinvest for growth
News Preview
Bagsværd, Denmark, 10 September 2025 – Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in diabetes and obesity. As part of the transformation, Novo Nordisk intends to reduce the global workforce by appro...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.09.2025
NOVO B
LISTED
CPH
Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress
News Preview
Bagsværd, Denmark, 5 September 2025 – Novo Nordisk today announced the presentation of 35 abstracts from across its diabetes and obesity portfolio at the upcoming European Association for the Study of Diabetes (EASD) congress 2025 from 15 to 19 September in Vienna, Austria. The presentations include clinical and real-world data reinforcing semaglut...
Themefolio
Profiler
Peergroup
© Globe Newswire
31.08.2025
NOVO B
LISTED
CPH
Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas
News Preview
Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy® (semaglutide 2.4 mg) c...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.08.2025
NOVO B
LISTED
CPH
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025
News Preview
Bagsværd, Denmark, 20 August 2025 – Novo Nordisk today announced new data showing the cardiovascular protective benefits of Wegovy® and Ozempic® will be presented at the European Society of Cardiology (ESC) Congress 2025 from 29 August to 1 September in Madrid, Spain. New data will also include perspectives on the role of inflammation in a conditio...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.08.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
News Preview
Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have...
Themefolio
Profiler
Peergroup
© Globe Newswire
15.08.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH
News Preview
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to ad...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
News Preview
Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
News Preview
Bagsværd, Denmark, 7 August 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.07.2025
NOVO B
LISTED
CPH
Novo Nordisk lowers sales and operating profit outlook for 2025
News Preview
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and operating profit outlook at CER....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.07.2025
NOVO B
LISTED
CPH
European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors
News Preview
Bagsværd, Denmark, 25 July 2025 – Novo Nordisk today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending an update of the Alhemo® (concizumab) label to include the treatment of severe haemophilia A and moderate or severe haemophilia B without inhibitors....
Themefolio
Profiler
Peergroup
© Globe Newswire
23.06.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
News Preview
Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.06.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
News Preview
Bagsværd, Denmark, 22 June 2025 – Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout period or Mim8 loading dose, was well-tolerated with no safety concerns in adults and adolescents living with haemophilia A...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.06.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
News Preview
Bagsværd, Denmark, 22 June – Today, The New England Journal of Medicine (NEJM) published results from Novo Nordisk’s phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions for weight loss in adults with obesity or overweight who have a weight-related medical complication and without dia...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
NOVO B
LISTED
CPH
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
News Preview
Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.06.2025
NOVO B
LISTED
CPH
Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
News Preview
Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or ob...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.06.2025
NOVO B
LISTED
CPH
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development
News Preview
Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies. The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities following end-of-phase 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.06.2025
NOVO B
LISTED
CPH
ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care
News Preview
Bagsværd, Denmark, 10 June – Novo Nordisk today announced that new data from its industry-leading portfolio in metabolic and cardiovascular health will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago US, 20 – 23 June 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
News Preview
Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
16.05.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk
News Preview
Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors....
Themefolio
Profiler
Peergroup
© Globe Newswire
12.05.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
News Preview
Bagsværd, Denmark, 12 May 2025 – Novo Nordisk today presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya® (somapacitan) was non-inferior to the once-daily growth hormone Norditropin® (somatropin) in improving yearly growth rate (as measured by height velocity [HV] at Week 52) in pre-pubertal children born small...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.05.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
News Preview
Bagsværd, Denmark, 9 May 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse....
Themefolio
Profiler
Peergroup
© Globe Newswire
07.05.2025
NOVO B
LISTED
CPH
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
News Preview
7 May 2025 - Financial report for the period 1 January 2025 to 31 March 2025 &...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.04.2025
NOVO B
LISTED
CPH
Novo Nordisk announces changes in Executive Management
News Preview
Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in Executive Management....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.03.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
News Preview
Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD)1. Thes...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.03.2025
NOVO B
LISTED
CPH
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
News Preview
Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from STRIDE, a phase 3b peripheral artery disease (PAD) outcomes trial investigating the effects of once-weekly injectable Ozempic® (semaglutide 1.0 mg) in adults with type 2 diabetes and PAD, at the American College of Cardiology's (ACC) Annual Scientific Session and...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
NOVO B
LISTED
CPH
Resolutions from the Annual General Meeting of Novo Nordisk A/S
News Preview
Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting....
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
NOVO B
LISTED
CPH
The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
News Preview
Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL’s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251,...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.03.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
News Preview
Bagsværd, Denmark, 10 March 2025 – Today, Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo. The tria...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.02.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
News Preview
Bagsværd, Denmark, 27 February 2025 – The Annual General Meeting of Novo Nordisk A/S will be held on:...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.02.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
News Preview
Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.02.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
News Preview
Bagsværd, Denmark, 6 February 2025 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.01.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S - share repurchase programme
News Preview
Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part o...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.01.2025
NOVO B
LISTED
CPH
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
News Preview
Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration....
Themefolio
Profiler
Peergroup
© Globe Newswire
20.01.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S - share repurchase programme
News Preview
Bagsværd, Denmark, 20 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part o...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.01.2025
NOVO B
LISTED
CPH
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
News Preview
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 randomised adu...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.12.2024
NOVO B
LISTED
CPH
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
News Preview
Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components c...
Themefolio
Profiler
Peergroup
© Globe Newswire
16.12.2024
NOVO B
LISTED
CPH
Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
News Preview
Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
14.12.2024
NOVO B
LISTED
CPH
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
News Preview
Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S’s pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Je...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.12.2024
NOVO B
LISTED
CPH
Novo Nordisk A/S - share repurchase programme
News Preview
Bagsværd, Denmark, 9 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part o...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
